HUTCHMED Licenses HMPL-A830 to GSK in $1.3 Billion KRAS-EGFR Deal

China-based HUTCHMED has entered into an exclusive worldwide license agreement with GSK for HMPL-A830, a first-in-class antibody-targeted therapy conjugate (ATTC) combining a KRAS inhibitor with an anti-epidermal growth factor receptor (anti-EGFR) antibody, the company announced September 3, 2026.¹ Under the agreement, HUTCHMED will receive a $110 million upfront payment and is eligible for up to $1.295 billion in total payments, including development, regulatory, and commercial milestones plus tiered royalties on net sales.¹

"We are proud to work with GSK, a globally leading biopharmaceutical company that, like HUTCHMED, is committed to developing innovative new cancer medicines to address significant unmet medical needs worldwide," said Johnny Cheng, acting chief executive officer and chief financial officer of HUTCHMED, in a company press release.¹ "HMPL-A830 is our third drug candidate from these novel payload platforms and the first from our platform to be licensed to a global partner, following two candidates that have entered clinical development."

How does HMPL-A830 work?

HMPL-A830 combines a selective KRAS small molecule inhibitor payload conjugated to an anti-EGFR antibody, designed to deliver the KRAS inhibitor directly to EGFR-expressing tumors while simultaneously blocking EGFR and KRAS signaling.¹ Unlike traditional cytotoxin-based antibody-drug conjugates, ATTCs are designed to combine targeted therapies to achieve synergistic anti-tumor activity. HUTCHMED said its ATTC platform has outperformed standalone antibody or small-molecule inhibitor components in efficacy and safety in preclinical models.¹

KRAS is mutated in approximately 44% of colorectal cancer, 34% of lung adenocarcinoma, and up to 89% of pancreatic ductal adenocarcinoma cases, and EGFR signaling is a known driver of resistance to KRAS-targeted therapies. These factors provide the rationale for dual targeting of both proteins.² Clinical development will initially focus on colorectal, pancreatic, and lung cancer.¹

What are the terms of the agreement?

According to the terms, HUTCHMED will conduct the global phase 1 development program, expected to begin in the second half of 2026 (NCT07718581), after which GSK will assume responsibility for all subsequent clinical development and commercialization outside mainland China, Hong Kong, Macau, and Taiwan, where HUTCHMED retains full rights.¹ GSK also holds a right of first negotiation on one earlier-stage ATTC candidate from HUTCHMED's pipeline.¹ BofA Securities acted as exclusive financial advisor to HUTCHMED on the transaction.¹

How does this deal fit into broader biopharma dealmaking trends?

The agreement reflects a broader wave of global pharmaceutical companies licensing clinical-stage assets originating from China-based biotechs. Deal flexibility has become an increasingly important structural feature in this type of long-horizon licensing agreement, in which a molecule entering early trials today may not reach the market for years.³

"Just because we're talking about these policy issues today doesn't mean 7 to 10 years from now, when these products actually launch, that you're going to see those same issues," said Oren Livne, co-chair of the North America Healthcare and Life Sciences Group at Baker McKenzie, in a previous interview with BioPharm International®.³ "So, having that more robust flexibility structure in those deals allows contracts to be flexible for the future."

What did GSK say about the deal?

"This agreement reflects GSK's growing leadership across oncology and our commitment to advance the latest innovation for patients living with cancer," said Hesham Abdullah, MD, senior vice president and global head of oncology R&D at GSK, in the company press release.¹ "The dual KRAS-EGFR mechanism of HMPL-A830 has the potential to significantly improve upon current standard of care."

What are the limitations?

HMPL-A830 has not yet entered clinical trials, and no human safety or efficacy data exist. Closing of the agreement remains subject to customary conditions, including completion of antitrust regulatory review.

References

1. HUTCHMED (China) Limited. HUTCHMED announces licensing agreement with GSK for KRAS-EGFR-antibody conjugate cancer therapy. Press release. Published September 3, 2026. Accessed September 3, 2026. https://www.hutch-med.com/hutchmed-gsk-licensing-agreement-kras-egfr-attc/
2. Singhal A, Li BT, O'Reilly EM. Targeting KRAS in cancer. Nat Med. 2024;30:969-983. doi:10.1038/s41591-024-02903-0
3. Jacobus N, Livne O, Mirasol F. Flexibility and AI-driven diligence are defining biopharma deal strategy in 2026, says Baker McKenzie's Oren Livne. BioPharm International. Published June 26, 2026. Accessed September 3, 2026. https://www.biopharminternational.com/view/flexibility-ai-biopharma-deal-strategy-baker-mckenzie-oren-livne